Fish Oil Emulsion Reduces Liver Injury and Liver Transplantation in Children with Intestinal Failure-Associated Liver Disease: A Multicenter Integrated Study

“Even When the Wound Is Healed, the Scar Remains”

“…The report by Gura et al 7 in this volume of The Journal provides data to support the observation by Pastor-Clerigues et al 8 that serum profibrotic markers and monocyte-produced transforming growth factor b1 are downregulated in patients transitioned from soy-based lipid to fish oil-based lipid. In the multicenter, cross-sectional study by Gura et al, 7 a surrogate marker for hepatic fibrosis, the aspartate amino transferase to platelet ratio index (APRI), was measured longitudinally in a cohort of patients treated with fish oil-based lipid. This was compared with that calculated retrospectively and longitudinally from historic control groups from Boston Children's Hospital and Mattel Children's Hospital who had received 2-3 g per kg per day of soy-based lipid.…”

Inhalation of nebulized omega-3 fatty acids mitigate LPS-induced acute lung inflammation in rats: Implications for treatment of COPD and COVID-19

“…O3FA are dietary, natural, endogenous metabolites that promote balanced inflammatory and thrombotic responses. The safety and efficacy of multigram oral and intravenous lipid emulsions has long been established in young children and adults [125] , [126] , [127] , [128] , [129] . A double-blind, randomized clinical trial showed oral O3FA improved the levels of several respiratory and renal function parameters in critically ill COVID-19 patients [130] .…”

Evaluation of the prognostic factors for pediatric intestinal motility disorders: A single institution experience

“…This suggests that the treatment of cholestasis is important for all IF patients. The major methods used to treat or prevent cholestasis is the administration of sh oil lipid emulsion such as Omegaven ® and SMOFlipid ® , and it may be most bene cial for infants who cannot tolerate enteral nutrition [17,18]. It is expected that sh oil lipid emulsion will be extensively used in our country to improve the mortality rate of patients with IMD.…”

“…[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17] days, CIIP: 3855.5 [3506-4205] days, p=0.089). Furthermore, the location of enterostomy did not differ to a statistically signi cant extent among the 3 groups (extensive aganglionosis: 15 cm, hypoganglionosis: 80 [5-100] cm, CIIP: 40 cm, p=0.186).…”